Cleveland Clinic and Mount Sinai Won’t Administer Aduhelm to Patients

The rejection of the new Alzheimer’s drug by the two major medical centers is one of the starkest signs of concern over its approval by the F.D.A.

In a striking reflection of concern over the approval of the controversial new Alzheimer’s drug Aduhelm, two major American health systems have decided that they will not administer it to patients. The Cleveland Clinic, one of the largest and most respected medical centers in the country, said in a statement that a panel of its experts had “reviewed all available scientific evidence on this medication,” which is also called aducanumab. “Based on the current data regarding its safety and efficacy, we have decided not to carry aducanumab at this time,” the statement said.